Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine (Q28353468)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine	scientific article

Statements

scholarly article

0 references

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine (English)

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

object named as

T K Kvien

0 references

author name string

D L Scott

1

0 references

J S Smolen

2

0 references

J R Kalden

3

0 references

L B van de Putte

4

0 references

A Larsen

5

0 references

M Schattenkirchner

7

0 references

P Nash

8

0 references

C Oed

9

0 references

I Loew-Friedrich

10

0 references

language of work or name

0 references

publication date

October 2001

0 references

Annals of the Rheumatic Diseases

0 references

60

0 references

913-23

0 references

10

0 references

Leflunomide: mode of action in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

20 March 2017

Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

20 March 2017

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Effects of leflunomide on immune responses and models of inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Variations in responses to non-steroidal anti-inflammatory drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

29 September 2017

Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Mechanism of action of leflunomide in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Currently used second-line agents: do they control the disease course?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Sulphasalazine in the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Comparison of standard and alternative health assessment questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Anti-inflammatory analgesic drug responders and non-responders: a clinico-pharmacological study of flurbiprofen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

2 June 2018

Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

27 November 2018

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

27 November 2018

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

27 November 2018

Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1753377

27 November 2018

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bone and joint decade 2000-2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treat

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirt

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of patient outcome in arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability in response to NSAID

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis. Support for the concept of “responders” and “nonresponders”

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time

1 reference

https://pubmed.ncbi.nlm.nih.gov/11557646

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.60.10.913

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28353468&oldid=1529001332"